TL;DR
This qualitative study explores the lived experiences of individuals co-infected with drug-resistant tuberculosis (DRTB) and HIV in South Africa, revealing significant disruptions across four stages of care: diagnosis, treatment initiation, discharge, and continuity. The findings highlight critical gaps in information, patient agency, and social support, underscoring the need for more patient-centered, community-based approaches to DRTB care, especially for those with HIV.
What Problem Does This Paper Address?
Drug-resistant tuberculosis (DRTB) is a severe and challenging form of the disease, with low treatment success rates and significant patient burdens. While new oral medications like bedaquiline have improved treatment options, there's limited understanding of how patients experience this care, particularly when they are also living with HIV. Existing research often provides snapshots of challenges but doesn't capture the dynamic, evolving needs of patients throughout their long treatment journeys. This paper aims to fill that gap by describing the longitudinal experiences of DRTB-HIV co-infected patients in South Africa, identifying disruptions and potential ameliorative strategies.
Methods
The study employed a qualitative approach, drawing on Bury's theory of biographical disruption, which examines how chronic illness impacts individuals' lives. Researchers conducted 13 focus groups with 55 patients co-infected with DRTB and HIV who were receiving bedaquiline-based treatment. Participants were categorized into three groups based on their stage of DRTB treatment: early (2-6 weeks), middle (2-6 months after discharge or initiation), and late (>6 months). Focus groups were conducted in isiZulu, audio-recorded, and translated to English. Thematic analysis was used to identify patterns and themes in the participants' narratives.
Datasets
Not discussed in the paper. The study utilized qualitative data gathered through focus groups with patients.
Key Insights and Ideas
- Biographical Disruption is Profound: DRTB and HIV treatment fundamentally alter patients' identities, relationships, daily lives, and financial stability, creating a "biographical disruption" that requires significant adaptation.
- Stigma is Pervasive and Shifting: Stigma is a constant companion, manifesting differently at each stage of care. It shifts from fear of contagion and medical procedures during diagnosis to social isolation and devaluation upon returning to the community. The co-infection with HIV often compounds this stigma.
- Information and Agency are Crucial Gaps: Patients consistently reported a lack of clear, accessible information about DRTB, especially compared to the information provided for HIV. This information deficit, coupled with a lack of agency in decision-making, exacerbates their challenges.
- Four Distinct Stages of Disruption: The study identified four key stages in the DRTB care cascade where patients experience specific disruptions:
- Diagnosis and Hospitalization: Marked by shock, fear, stigma, and a lack of choice regarding admission.
- Treatment Initiation: Characterized by side effects, isolation, and a high pill burden, leading to feelings of being displaced and confined.
- Discharge Home: Initially a reprieve, this stage brings resurgent disruption due to family resentment, social isolation, and the difficulty of self-management.
- Treatment Continuity: Characterized by persistent side effects, fragmented care, and a sense of "no end in sight," leading to financial strain and loss of self-worth.
- Resilience Factors Emerge: Despite the disruptions, patients found resilience through peer connections, self-isolation, financial/material security (often from family), and a strong focus on recovery. Faith and prayer also played a significant role.
- HIV Care as a Model: Patients often contrasted the more established, patient-centered care for HIV with the less developed approach for DRTB, highlighting the need to integrate lessons learned from HIV programs.
Key Results
The study identified numerous disruptive experiences and ameliorative strategies across the four stages of DRTB treatment. Key disruptive experiences included:
- Diagnosis/Hospitalization: Stigmatizing treatment (masks, separate queues), admission to a centralized hospital without notice or choice, renunciation of social commitments, and fear of the unknown.
- Treatment Initiation: Significant side effects (nausea, headache, joint pain), a high pill burden (22-30 pills daily), disconnection from social networks, and provider apathy or stigma.
- Discharge Home: Difficulty adjusting to household routines, family resentment, social isolation, and the challenge of self-managing medication and side effects.
- Treatment Continuity: Persisting side effects (skin pigmentation, limb pain), fragmented healthcare, financial debt, and a deepening sense of stigma and loss of self-worth.
Ameliorative strategies identified included:
- Diagnosis/Hospitalization: Pre- and post-test counseling, information on disease and treatment, primary care provider training, and family engagement.
- Treatment Initiation: Monitoring and management of side effects, connection to peers and family, and specialized care provider training.
- Discharge Home: Early discharge planning, decentralized monitoring, family engagement, and community awareness programs.
- Treatment Continuity: Decentralized monitoring, differentiated service delivery, side-effect management, and social protection.
Limitations and Future Work
The authors acknowledge several limitations:
- Inability to follow participants over time: The study used focus groups at different stages rather than a true longitudinal design, which might have missed some nuances of change.
- Focus groups vs. individual interviews: While focus groups were chosen for cultural appropriateness in discussing sensitive topics, they may not have captured the full depth of individual experiences.
- Limited triangulation: The study did not triangulate adherence data beyond self-reported pill-taking in focus groups.
Future work could explore these limitations by using individual interviews for deeper longitudinal data. The study's findings strongly suggest the need for:
- Patient-centered interventions: Tailoring care to individual needs and stages of treatment.
- Improved information and communication: Providing clear, accessible information about DRTB, similar to HIV care.
- Enhanced social support: Strengthening institutional, community, and household support systems.
- Decentralization of care: Moving DRTB treatment closer to patients' homes, leveraging lessons from HIV and other infectious disease programs.
- Addressing stigma: Implementing destigmatizing and rights-based approaches to infectious disease care.
Summary updated